Peripheral Vascular Disease

WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.

WASHINGTON — In an exploratory analysis of the PROTECTED TAVR trial of patients undergoing transcatheter aortic valve replacement, cerebral embolic protection reduced risk for short-term stroke in patients from the U.S. but not elsewhere.

Abbott announced the FDA approved elimination of aspirin as part of routine management from the label of its fully magnetically levitated left ventricular assist device.

BOSTON — Emerging data on the cardiovascular benefits of GLP-1 receptor agonists indicate that these agents could transform cardiovascular care, much like statins did 30 years ago, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, said.

Compared with angiography, IVUS may improve care and outcomes of patients requiring interventional peripheral revascularization, according to an expert consensus roundtable sponsored by several medical societies.

Compared with white patients, Black and Hispanic patients with peripheral vascular disease are younger, have more comorbidities, are less likely to undergo revascularization and more likely to undergo amputation, national data show.

A joint statement outlines competency-based training requirements for interventional cardiology trainees across three subspecialties, offering a “roadmap” for program directors and trainees for required procedural and technical experience.

Patients with psoriatic disease had a higher incidence of venous thromboembolism and peripheral vascular disease, according to a study.

At 5 years, there was no link between a paclitaxel-coated balloon and excess mortality compared with percutaneous transluminal angioplasty in two studies of patients with peripheral artery disease.